JP2023518035A5 - - Google Patents

Info

Publication number
JP2023518035A5
JP2023518035A5 JP2022555625A JP2022555625A JP2023518035A5 JP 2023518035 A5 JP2023518035 A5 JP 2023518035A5 JP 2022555625 A JP2022555625 A JP 2022555625A JP 2022555625 A JP2022555625 A JP 2022555625A JP 2023518035 A5 JP2023518035 A5 JP 2023518035A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
inhibitor
halo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022555625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518035A (ja
JP7744358B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/079464 external-priority patent/WO2021184154A1/en
Application filed filed Critical
Publication of JP2023518035A publication Critical patent/JP2023518035A/ja
Publication of JP2023518035A5 publication Critical patent/JP2023518035A5/ja
Application granted granted Critical
Publication of JP7744358B2 publication Critical patent/JP7744358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022555625A 2020-03-16 2021-03-15 急性骨髄性白血病の再発を処置または阻害するための化合物 Active JP7744358B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/079464 2020-03-16
PCT/CN2020/079464 WO2021184154A1 (en) 2020-03-16 2020-03-16 Compounds for treating or inhibiting recurrence of acute myeloid leukemia
PCT/US2021/022322 WO2021188417A1 (en) 2020-03-16 2021-03-15 Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Publications (3)

Publication Number Publication Date
JP2023518035A JP2023518035A (ja) 2023-04-27
JP2023518035A5 true JP2023518035A5 (cg-RX-API-DMAC7.html) 2024-03-27
JP7744358B2 JP7744358B2 (ja) 2025-09-25

Family

ID=77767943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555625A Active JP7744358B2 (ja) 2020-03-16 2021-03-15 急性骨髄性白血病の再発を処置または阻害するための化合物

Country Status (15)

Country Link
US (1) US11963960B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121430A4 (cg-RX-API-DMAC7.html)
JP (1) JP7744358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102990081B1 (cg-RX-API-DMAC7.html)
CN (1) CN115298180B (cg-RX-API-DMAC7.html)
AR (1) AR121570A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020436612A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018345A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168988A1 (cg-RX-API-DMAC7.html)
IL (1) IL296296A (cg-RX-API-DMAC7.html)
MX (1) MX2022011407A (cg-RX-API-DMAC7.html)
PE (1) PE20230461A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552169A1 (cg-RX-API-DMAC7.html)
TW (1) TWI899184B (cg-RX-API-DMAC7.html)
WO (2) WO2021184154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
AU2021289345A1 (en) * 2020-06-08 2023-01-19 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
CN114075190A (zh) 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
CN113861179A (zh) * 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用
WO2025124429A1 (zh) * 2023-12-11 2025-06-19 北京康辰药业股份有限公司 芳香胺化合物及其药物组合物、应用
WO2025151010A1 (ko) * 2024-01-11 2025-07-17 주식회사 펠레메드 신규한 피롤로트리아진 유도체 및 이의 용도
KR20250157634A (ko) 2024-04-29 2025-11-05 대한민국(질병관리청 국립보건연구원장) Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808281A (pt) 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2005074603A2 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
US7772231B2 (en) 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
JP6327713B2 (ja) 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
USRE48175E1 (en) * 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
US20190255056A1 (en) 2016-09-15 2019-08-22 Riken A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
AU2020301399B2 (en) 2019-06-24 2025-12-18 Dana-Farber Cancer Institute, Inc. HCK degraders and uses thereof
CN114746095B (zh) 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
MX2022008148A (es) * 2020-01-02 2022-07-21 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de btk.
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Similar Documents

Publication Publication Date Title
JP6505013B2 (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2026031940A (ja) Shp2の活性を阻害するための化合物の製造方法
CN101663282B (zh) 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物
EP3917916A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP4220897B2 (ja) ピペラジン化合物
JP2007505931A5 (cg-RX-API-DMAC7.html)
JP2009537550A5 (cg-RX-API-DMAC7.html)
JP2023533447A5 (cg-RX-API-DMAC7.html)
CN107660202B (zh) 水溶性前药
ES3055488T3 (en) Tegavivint for use in the treatment of pulmonary fibrosis
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
JP2022522486A5 (cg-RX-API-DMAC7.html)
JP2010521483A5 (cg-RX-API-DMAC7.html)
JP2020505457A (ja) 2−アリールスルホンアミド−N−アリールアセトアミド誘導体化Stat3
CN102482256B (zh) N-取代的环状氨基衍生物
JP2015521617A5 (cg-RX-API-DMAC7.html)
JPWO2008099874A1 (ja) ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法
JP2022537140A5 (cg-RX-API-DMAC7.html)
IL290882B1 (en) Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
AU2020221247B2 (en) Formulations comprising heterocyclic protein kinase inhibitors
EP3860991A1 (en) Monomer and multimeric anti-hbv agents
IL293703A (en) Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms
JP2012506908A5 (cg-RX-API-DMAC7.html)
JP2006512321A5 (cg-RX-API-DMAC7.html)